both products are still used a lot in AU. and of course in 2nd & 3rd world a lot more. As for ACR going bust...........? I have no idea. IF we achieve cashflow positive in 4 months or very close to it ......... ACR should prevail long term. In my mind I'm thinking ( a very very speculative guess on my part) that most generics will earn for ACR anywhere from US$ 1/2 a cent to, if lucky , 2 cents a share. there's some 282 odd million outstanding shares. Once we have the Testosterone figures, which should earn more than say Elma Cream, that will be a benchmark of sorts. we will be able to look at total US market sales of a product(s)....... number of players in each segment.... and see overall what sort of market % were getting. So if we start averaging (example only) 2-3% on each product that may end up being a very rough guide to how each new launched product goes.
- Forums
- ASX - By Stock
- News: ACR Acrux Says Its Sixth Generic Application Accepted By U.S. FDA For Review
ACR
acrux limited
Add to My Watchlist
0.00%
!
2.0¢

both products are still used a lot in AU. and of course in 2nd &...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
2.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.155M |
Open | High | Low | Value | Volume |
2.0¢ | 2.0¢ | 2.0¢ | $12.32K | 616.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 425000 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 286349 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 425000 | 0.019 |
3 | 381800 | 0.018 |
3 | 472000 | 0.017 |
1 | 66732 | 0.015 |
1 | 70000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 286349 | 2 |
0.021 | 80630 | 1 |
0.022 | 204574 | 4 |
0.023 | 115126 | 4 |
0.024 | 306848 | 8 |
Last trade - 10.02am 18/06/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online